Lifecare ASA

Earnings Release • Nov 12, 2025

LIFE: Lifecare ASA Q3 2025 results

LIFE: Lifecare ASA Q3 2025 results

Bergen, Norway, 12 November 2025: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), publishes its Q3 2025 financial report and operational update.

Highlights:

* Secured NOK 80 million, supporting next development and regulatory

milestones

* Finalized product design and production setup, positioning for near-term

veterinary market entry

* Entered final regulatory review phase for first-in-human clinical approval

Diabetes affects over 600 million people worldwide, creating growing demand

for reliable and driving rapid glucose monitoring. Lifecare is developing a

fully implantable, miniaturized Continuous Glucose Monitoring (CGM) system

designed for long-term accuracy, ease of use, and cost efficiency, advancing

toward clinical validation and future commercialization.

Q3 focused on securing financing to ensure sufficient working capital and

continued product development. While operations largely stayed on plan,

liquidity constraints required a temporary slowdown in production workstreams,

delaying completion of devices needed for the longevity trial LFC-SEN-002.

At the end of October, the Board announced a partially underwritten rights

issue expected to raise NOK 80--100 million in January 2026, to be followed by

two warrant exercise periods. Bridge financing will ensure operations until

completion of the rights issue. The planned financing will enable continued

product development, support the veterinary market launch, and advance CE-mark

preparations for the human market. For further details regarding the

financing, please refer to Note 9.

Early results from the longevity trial in dogs confirm excellent

biocompatibility, safety, and reliable end-to-end glucose data transmission.

Based on these findings, we have implemented improvements to material

stability, antenna design, and firmware performance. A new batch of devices is

expected to be ready for implantation in dogs in December.

Preparations for our first-in-human trial (FIH) are progressing. While

regulatory approval was initially expected in Q3 2025, the evaluation process

has taken longer than anticipated. At the end of October, the Norwegian

Medical Products Agency (NoMA) validated our application, confirming that the

documentation is complete and compliant. Final approval may be granted by

mid-December 2025, allowing study initiation in Q1 2026. This pilot study will

provide essential clinical validation ahead of the pivotal CE-marking trial in

2026, paving the way for a commercial launch in Europe in 2027.

Our team remains focused, disciplined, and dedicated to achieving Lifecare's

next major milestone - bringing our novel CGM technology from development to

clinical trials for diabetes patients, while creating lasting value for our

shareholders.

Q3 2025 results presentation:

CEO Joacim Holter and CFO Renete Kaarvik will present live on webcast today at

10:00 a.m. CET.

To access the webcast Join the meeting here.

(https://eur04.safelinks.protection.outlook.com/ap/t-59584e83/?url=https%3A%2F%2Fteams.microsoft.com%2Fl%2Fmeetup-join%2F19%253ameeting_MjhiMDliMmUtZmU3YS00MmQ3LWFmZjAtMjFkYTM2ODA4NzJi%2540thread.v2%2F0%3Fcontext%3D%257b%2522Tid%2522%253a%252210b30f00-1bbd-4041-9c4d-64749f4a7041%2522%252c%2522Oid%2522%253a%25223758e62c-12e5-4419-a645-4b77ef5225be%2522%257d&data=05|02|asle.wingsternes%40lifecare.no|02ab5775069c4453b5b308de187b70da|c5fbb1c64eb045db9f3c6e20ebcd710e|0|0|638975115642037858|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=H%2B69p81%2FuJ%2FRcOUfC%2FO9leLDEu9GxppO%2FQ7q47qgW6M%3D&reserved=0)

A recording of the webcast will be available on our website after the event.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 17. The information was submitted for publication at

2025-11-12 07:00 CET.